Insmed FY2025 EPS Estimate Reduced by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has revised its earnings forecast for Insmed, predicting a loss of $5.62 per share for FY2025, which is a decrease from the previous estimate of $5.37.
• Despite the earnings downgrade, several brokerages maintain a positive outlook on Insmed, with price targets ranging between $120.00 and $142.00.
• Insmed's stock recently decreased by 0.9% to $126.58, and the company reported a quarterly EPS loss of ($1.70), missing analysts' expectations.

Insmed, Inc. (NASDAQ:INSM - Free Report) - Research analysts at Cantor Fitzgerald cut their FY2025 earnings estimates for shares of Insmed in a note issued to investors on Wednesday, August 13th. Cantor Fitzgerald analyst J. Kim now forecasts that the biopharmaceutical company will post earnings of ($5.62) per share for the year, down from their prior estimate of ($5.37). The consensus estimate for Insmed's current full-year earnings is ($4.56) per share. Cantor Fitzgerald also issued estimates for Insmed's FY2026 earnings at ($4.74) EPS.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.40). The company had revenue of $107.42 million during the quarter, compared to the consensus estimate of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%. The firm's revenue for the quarter was up 18.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.94) earnings per share.

A number of other analysts have also recently commented on the company. Leerink Partners upped their price target on Insmed from $100.00 to $115.00 and gave the company an "outperform" rating in a research note on Tuesday, June 10th. UBS Group upped their target price on shares of Insmed from $124.00 to $133.00 and gave the company a "buy" rating in a research note on Friday, August 8th. Bank of America lifted their price target on shares of Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a research report on Wednesday, June 11th. Stifel Nicolaus boosted their price target on shares of Insmed from $121.00 to $145.00 and gave the company a "buy" rating in a report on Thursday. Finally, Jefferies Financial Group raised their price objective on Insmed from $129.00 to $148.00 and gave the stock a "buy" rating in a research note on Wednesday, August 13th. One equities research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $129.57.

Insmed Trading Down 0.4%

NASDAQ:INSM traded down $0.53 during mid-day trading on Friday, hitting $127.27. The company had a trading volume of 3,425,401 shares, compared to its average volume of 3,039,765. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. Insmed has a fifty-two week low of $60.40 and a fifty-two week high of $130.13. The firm has a market cap of $26.90 billion, a P/E ratio of -22.29 and a beta of 0.95. The business's fifty day moving average is $104.75 and its two-hundred day moving average is $84.33.

Insider Transactions at Insmed

In other Insmed news, insider Michael Alexander Smith sold 933 shares of the business's stock in a transaction that occurred on Tuesday, July 15th. The stock was sold at an average price of $102.51, for a total value of $95,641.83. Following the sale, the insider owned 66,394 shares in the company, valued at approximately $6,806,048.94. The trade was a 1.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the company's stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $93.42, for a total value of $9,264,648.24. Following the transaction, the insider directly owned 89,407 shares of the company's stock, valued at approximately $8,352,401.94. This trade represents a 52.59% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 525,716 shares of company stock valued at $49,665,671. 3.00% of the stock is currently owned by company insiders.

Institutional Trading of Insmed

Hedge funds and other institutional investors have recently made changes to their positions in the business. CANADA LIFE ASSURANCE Co boosted its holdings in Insmed by 8.9% during the second quarter. CANADA LIFE ASSURANCE Co now owns 46,250 shares of the biopharmaceutical company's stock worth $4,664,000 after purchasing an additional 3,792 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Insmed by 510.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 45,235 shares of the biopharmaceutical company's stock valued at $4,552,000 after buying an additional 37,820 shares during the last quarter. Corient Private Wealth LLC lifted its position in Insmed by 22.0% during the 2nd quarter. Corient Private Wealth LLC now owns 15,024 shares of the biopharmaceutical company's stock worth $1,515,000 after buying an additional 2,705 shares in the last quarter. Sender Co & Partners Inc. acquired a new position in shares of Insmed during the 2nd quarter worth about $218,000. Finally, Voleon Capital Management LP acquired a new position in shares of Insmed during the 2nd quarter worth about $480,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.